For Debate: Starling's Curve of the Pancreas - Overuse of a Concept?

Abstract

It is commonly accepted that insulin secretion follows the pattern of an inverted U, also termed ‘Starling's curve of the pancreas’ during the natural history of hyperglycemia in glucose intolerance and type 2 diabetes. This concept is based on the cross-sectional observation that insulin concentrations initially increase when insulin sensitivity declines (as a consequence of obesity, for example) and decrease when glucose tolerance deteriorates (impaired glucose tolerance or overt type 2 diabetes). The initial increase in insulin concentrations has been viewed as ‘hypersecretion’ of insulin, thought to indicate that beta cell dysfunction is not etiological but secondary in nature. However, this view is oblivious to the now well-established fact that assessment of insulin secretion must account for individual insulin sensitivity. Here, we revisit the concept of Starling's curve of the pancreas based on first-phase C-peptide concentrations (hyperglycemic clamp) from subjects with normal glucose tolerance (n = 66), impaired glucose tolerance (n = 19) and mild type 2 diabetes (n = 9). In absolute terms, first-phase C-peptide concentrations plotted against increasing fasting glucose concentrations indeed followed an inverted U. However, adjusted for direct and indirect measures of insulin sensitivity (insulin sensitivity index from the hyperglycemic clamp, body mass index, age and sex), first-phase C-peptide concentrations of the same individuals tended to decrease steadily. In conclusion, while the Starling curve exists for insulin concentrations, and perhaps also for insulin secretion, it does not hold for beta-cell function if that term were to imply appropriateness of insulin secretion (based on a formal test of glucose-stimulated insulin secretion) for the degree of insulin resistance, as it should.

References

• 1 DeFronzo R A. The triumvirate: B-cell, muscle, and liver: a collusion responsible for NIDDM.  Diabetes. 1988;  37 667-687
• 2 DeFronzo R A, Ferrannini E, Simonson D C. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.  Metabolism. 1989;  38 387-395
• 3 Sicree R A, Zimmet P Z, King H O, Coventry J S. Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 yr.  Diabetes. 1987;  36 179-186
• 4 Bogardus C, Lillioja S, Howard B, Reaven G, Mott D. Relationship between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects.  J Clin Invest. 1984;  74 1238-1246
• 5 Martin F I, Wyatt G B, Griew A R, Haurahelia M, Higginbotham L. Diabetes mellitus in urban and rural communities in Papua New Guinea. Studies of prevalence and plasma insulin.  Diabetologia. 1980;  18 369-374
• 6 Reaven G M, Miller R G. An attempt to define the nature of chemical diabetes using a multidimensional analysis.  Diabetologia. 1979;  16 17-24
• 7 Zimmet P, Whitehouse S. Bimodality of fasting and two-hour glucose tolerance distributions in a Micronesian population.  Diabetes. 1978;  27 793-800
• 8 Zimmet P, Whitehouse S, Alford F, Chisholm D. The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance.  Diabetologia. 1978;  15 23-27
• 9 Savage P J, Dippe S E, Bennett P H, Gorden P, Roth J, Rushforth N B, Miller M. Hyperinsulinemia and hypoinsulinemia. Insulin responses to oral carbohydrate over a wide spectrum of glucose tolerance.  Diabetes. 1975;  24 362-368
• 10 Welborn T A, Stenhouse N S, Johnstone C G. Factors determining serum-insulin response in a population sample.  Diabetologia. 1969;  5 263-266
• 11 Reaven G, Miller R. Study of the relationship between glucose and insulin responses to an oral glucose load in man.  Diabetes. 1968;  17 560-569
• 12 Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen M R, Tuomi T, Groop L C. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study.  Diabetes. 2000;  49 975-980
• 13 Stumvoll M, Fritsche A, Volk A, Stefan N, Madaus A, Maerker E, Teigeler A, Koch M, Machicao F, Häring H. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose tolerant humans.  Diabetes. 2001;  50 882-885
• 14 Fritsche A, Stefan N, Hardt E, Schützenauer S, Häring H, Stumvoll M. A novel hyperglycemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.  Eur J Clin Invest. 2000;  30 411-418
• 15 Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M. Characterisation of beta-cell dysfunction of impaired glucose tolerance. Evidence for impairment of incretin-induced insulin secretion.  Diabetologia. 2000;  43 852-858
• 16 Stumvoll M, Fritsche A, Stefan N, Haring H. A 60 minute hyperglycemic clamp is sufficient to assess both phases of insulin secretion.  Horm Metab Res. 2000;  32 230-232
• 17 Mitrakou A, Vuorinen-Markkola H, Raptis G, Toft I, Mokan M, Strumph P, Pimenta W, Veneman T, Jenssen T, Bolli G, Korytkowski M, Yki-Järvinen H, Gerich J. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp.  J Clin Endocrinol Metab. 1992;  75 379-382
• 18 van Cauter E, Mestrez F, Sturis J, Polonsky K S. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C- peptide clearance.  Diabetes. 1992;  41 368-377
• 19 Bergman R N, Ader M, Huecking K, van Citters G. Accurate Assessment of beta-Cell Function: The Hyperbolic Correction.  Diabetes. 2002;  51 Suppl 1 S212-S220
• 20 Pratley R E, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus.  Diabetologia. 2001;  44 929-945
• 21 Mittelman S D, van Citters G W, Kim S P, Davis D A, Dea M K, Hamilton-Wessler M, Bergman R N. Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response.  Diabetes. 2000;  49 2116-2125
• 22 Weyer C, Bogardus C, Mott D M, Pratley R E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.  J Clin Invest. 1999;  104 787-794